Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.

Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.

The present invention relates generally to the field of disorders of complement activation. More specifically, the present invention provides methods and compositions useful for identifying patients having a complement-mediated disease that could benefit from treatment with complement inhibitors. As described herein, the present invention utilizes patient sera and flow cytometry in the companion diagnostic assay. More specifically, the present invention comprises evaluating complement activity via cell surface deposition of C5b-9 and, in further embodiments, complement-dependent cell killing (the modified Ham assay) using patient sera.

Provided herein are immunomodulatory proteins comprising variant PD-L1 and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.

The present invention relates to the treatment of diseases relating to proteins of the human microbiome metasecretome and, thus, to microbiome interactions, especially microbiome-host interactions. In particular the present invention relates to a method for identification of secreted peptides and proteins of the human microbiome. The present invention also relates to methods for generating a database of human microbiome metasecretome protein sequences. Furthermore, the present invention relates to a method for preparing a protein of the human microbiome metasecretome as well as to the use of such proteins in medicine.

The present invention relates to the treatment of diseases relating to proteins of the human microbiome metasecretome and, thus, to microbiome interactions, especially microbiome-host interactions. In particular the present invention relates to a method for identification of secreted peptides and proteins of the human microbiome. The present invention also relates to methods for generating a database of human microbiome metasecretome protein sequences. Furthermore, the present invention relates to a method for preparing a protein of the human microbiome metasecretome as well as to the use of such proteins in medicine.

This invention provides modified IGFBP-derived peptides—collectively termed “immodulator peptides”—and related compositions and methods. Chemical modifications to peptides using small molecules, and sequence extensions to immodulator core sequences exhibit new and surprising biological activities. The invention builds the combinatorial power of the immodulator peptide class further by demonstrating which core sequences bind metal or glycosaminoglycans such as heparin. The invention discloses some surprising biological properties of compositions derived from these modifications, including a host of new therapeutic and diagnostic utilities (e.g. immune modulation of TLR signaling, enhanced collagen synthesis by skin fibroblasts, and synergy with a RIG-1 agonist in killing melanoma cells). The invention also teaches methods for enhancing previously disclosed uses of immodulator peptides by showing how the modifications of the invention can boost the efficacy of immodulator peptides in a model of burn trauma.

This invention provides modified IGFBP-derived peptides—collectively termed “immodulator peptides”—and related compositions and methods. Chemical modifications to peptides using small molecules, and sequence extensions to immodulator core sequences exhibit new and surprising biological activities. The invention builds the combinatorial power of the immodulator peptide class further by demonstrating which core sequences bind metal or glycosaminoglycans such as heparin. The invention discloses some surprising biological properties of compositions derived from these modifications, including a host of new therapeutic and diagnostic utilities (e.g. immune modulation of TLR signaling, enhanced collagen synthesis by skin fibroblasts, and synergy with a RIG-1 agonist in killing melanoma cells). The invention also teaches methods for enhancing previously disclosed uses of immodulator peptides by showing how the modifications of the invention can boost the efficacy of immodulator peptides in a model of burn trauma.

Provided are an anti-ST2 antibody or a fragment thereof. The antibody or the fragment thereof can be specifically bound to human ST2, for inhibiting combination of IL-33 and human ST2, blocking an IL-33/ST2 intracellular signaling pathway, and inhibiting the promoting effect of different forms of IL-33 in cell-derived IL5, IL6 and 118 production. Compared with a known anti-ST2 antibody, this anti-ST2 antibody has higher biological activity, and can be used for preventing, treating or alleviating diseases related to ST2 expression or IL-33/ST2 pathway disorders.

The disclosure is directed to compositions comprising a prodrug and an immunomodulator, which can self-assemble into a nanofiber hydrogel at the site of application in a human. The prodrug comprises one or more cytotoxic agents conjugated to a hydrophilic moiety by a linker. The compositions may be used to kill cancer cells, such as glioblastoma and colorectal cancer cells.